This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


ViaCyte, Inc.

Drug Names(s): VC01, VC 01

Description: The therapy called VC-01 is a combination product integrated from two of its novel technologies, PEC-01 cells and the Encaptra drug delivery system. PEC-01 cells is a proprietary pancreatic endoderm cell product derived through directed differentiation of an inexhaustible human embryonic stem cell line, and the Encaptra drug delivery system is a proprietary immune-protecting and retrievable encapsulation medical device.

Deal Structure: ViaCyte and Janssen Biotech
In February 2016, ViaCyte and Janssen Biotech have agreed to consolidate the assets of the Janssen BetaLogics group into ViaCyte. The agreement provides ViaCyte with an exclusive license to all BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.

VC-01 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug